Page 54 - Pro-active Management of Women’s Health after Cardiometabolic Complicated Pregnancies

52 | Part 2 Cardiovascular Health
Table 2.2.4. Overview of studies on preeclampsia and thrombophilia (C= cohort study, C-C= Case-control study, PC= prospective cohort study, SR= systematic review, SPE= severe preeclampsia, MPE= mild preeclampsia, PlacPath= placental pathology, ACA= anti-cardiolipin antibodies, LAC= lupus anti-coagulans,
Study- Study Type
Current C
1995, Dekker et al104 C 2001, Many et al111 C
2002, Sikkema et al99 C-C 2005, Mello et al105 C-C 2006, Van Rijn et al112 C
2008, Muetze et al113 C 2009, Facchinetti et al114 C
2009, Kahn et al115 C-C 2010, Sep et al116 C 2010, Sep et al116 C
1995, Yasuda et al106 PC 1998, Nagy et al118 C-C 1999, Kupferminc et al119 C-C 1999, Mello et al120 C-C 1999, O’Shaughnessy et al121 C 1999, Van Pampus et al110 C-C 2000a, Kupferminc et al122 C-C
2000b, Kupferminc et al123 C-C 2001, Alfirevic et al107 C-C 2001, Dreyfus et al124 C-C 2002, Agorastos et al125 C-C 2002, Benedetto et al126 C-C
2002, Currie et al127 C-C 2002, D’Elia et al128 C-C
2000, Murphy et al130 PC 2004, Salomon et al131 PC 2005, Dizon-Thownson et al132 PC 2006, Lindqvist et al133 PC
2008, Karakantza et al134 PC 2008, Dudding et al135 PC 2008, Clark et al136 PC 2010, Silver et al137 PC
Comparisons
*
±SPE
±SPE, ±IUGR, ±PlacPath ±PlacPath ±SPE, ±MPE PE±HELLP, PE±IUGR, ±28w ±HELLP
±SPE
±PE PE±HELLP PE±HELLP
PE±S, ±IUGR ±SPE
±SPE, ±IUGR ±PE
±PE
±SPE, ±28w ±SPE, ±MPE, ±IUGR
±SPE
±SPE, ±IUGR ±PE
±PE, ±IUGR ±PE, PE±HELLP, PE±IUGR
±SPE
±PE
±PE, ±IUGR ±PE, ±IUGR ±PE, ±IUGR ±PE, ±IUGR, ±33w
±PE, ±IUGR ±PE, ±IUGR ±PE, ±IUGR ±PE, ±IUGR
n (PE)
890
101 25
47 402 120
68 60
113 75 40
22
69
34
46
283
345
80
63
63
180
16
111
48 58
12 29 134 34
8 243 66 129
All
32.9%
AFS
ACA LAC PCD 9.0% 1.9% 0.7%
28.4% 0.0% 1.2% 48.0%
68% 16.7% 24%
46.7%
4% 7% 3.2%
0.8% 2.5% 35% 20%
8% 3% 0% 9% 0% 3%
Robertson 2006117 SR
±PE, ±IUGR
481 8.9%
9.1%
2.9%
66.7%
31.2%
2.2% 2.2%
3.2%
14.3% 9.5% 3.9% 0.6%
Rodger 2010129
SR
±PE, ±IUGR
1060
34.5%